STOCKHOLM, Dec. 6, 2021 /PRNewswire/ -- XNK Therapeutics AB ("XNK") today announced it will perform a proof of concept study in acute myeloid leukemia (AML) using patient samples from The University of Texas MD Anderson Cancer Center. The proof of concept study is to determine feasibility...
from PR Newswire: https://ift.tt/3xWcEFZ
No comments:
Post a Comment